Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). They are committed to developing disease modifying and lifesaving treatments.
Acclime is a great business partner to work with. They offer a one-stop service to cover everything required to manage an Australian subsidiary.
Having worked with Acclime in two R&D incentive applications, I highly recommend Acclime to other biotech companies who are considering setting up a subsidiary in Australia.
Acclime has been instrumental in guiding us successfully through the R&D Tax Incentive program to conduct clinical trials in Australia. Even though I had prior experience in applying this program, I have relied heavily reply on Acclime to keep our company compliant and up to date with local changes.
VP Finance, Blade Therapeutics